A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anas...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Karger Publishers
2009-07-01
|
| Series: | Case Reports in Oncology |
| Subjects: | |
| Online Access: | http://www.karger.com/Article/FullText/229245 |
| _version_ | 1819075401720266752 |
|---|---|
| author | Erin D. Powell D.Blair Macdonald Akram M. Elkeilani Timothy R. Asmis |
| author_facet | Erin D. Powell D.Blair Macdonald Akram M. Elkeilani Timothy R. Asmis |
| author_sort | Erin D. Powell |
| collection | DOAJ |
| description | A 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anastomosis were performed. Final pathology revealed a primary appendiceal adenocarcinoma, poorly differentiated, of signet ring cell type. CT scan postoperatively revealed gross residual disease. The patient was treated with FOLFOX chemotherapy combined with bevacizumab. Repeat CT scan showed a decrease in residual disease and the patient clinically improved. After her treatment has been continued for 13 months, she remains clinically well and her CT scan shows sustained disease stability. Disseminated appendiceal carcinoma is generally considered to be refractory to 5-FU-based chemotherapy and, to our knowledge, this is the first reported case of a patient with appendiceal adenocarcinoma demonstrating clinical benefit and sustained stability of disease with combination chemotherapy plus bevacizumab. |
| first_indexed | 2024-12-21T18:24:50Z |
| format | Article |
| id | doaj.art-0ec36a5237dc4f94ad1d1d488403e9ae |
| institution | Directory Open Access Journal |
| issn | 1662-6575 |
| language | English |
| last_indexed | 2024-12-21T18:24:50Z |
| publishDate | 2009-07-01 |
| publisher | Karger Publishers |
| record_format | Article |
| series | Case Reports in Oncology |
| spelling | doaj.art-0ec36a5237dc4f94ad1d1d488403e9ae2022-12-21T18:54:27ZengKarger PublishersCase Reports in Oncology1662-65752009-07-012211111510.1159/000229245229245A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and BevacizumabErin D. PowellD.Blair MacdonaldAkram M. ElkeilaniTimothy R. AsmisA 44-year-old woman presented with lower abdominal pain and bilateral ovarian masses on ultrasound. Exploratory laparotomy revealed extensive peritoneal and intra-abdominal disease and an abnormal appendix. Bilateral salpingo-oophorectomy, infracolic omentectomy, ileocolic resection and primary anastomosis were performed. Final pathology revealed a primary appendiceal adenocarcinoma, poorly differentiated, of signet ring cell type. CT scan postoperatively revealed gross residual disease. The patient was treated with FOLFOX chemotherapy combined with bevacizumab. Repeat CT scan showed a decrease in residual disease and the patient clinically improved. After her treatment has been continued for 13 months, she remains clinically well and her CT scan shows sustained disease stability. Disseminated appendiceal carcinoma is generally considered to be refractory to 5-FU-based chemotherapy and, to our knowledge, this is the first reported case of a patient with appendiceal adenocarcinoma demonstrating clinical benefit and sustained stability of disease with combination chemotherapy plus bevacizumab.http://www.karger.com/Article/FullText/229245Appendiceal adenocarcinomaFOLFOXBevacizumabClinical benefitDisease stability |
| spellingShingle | Erin D. Powell D.Blair Macdonald Akram M. Elkeilani Timothy R. Asmis A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab Case Reports in Oncology Appendiceal adenocarcinoma FOLFOX Bevacizumab Clinical benefit Disease stability |
| title | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
| title_full | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
| title_fullStr | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
| title_full_unstemmed | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
| title_short | A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab |
| title_sort | case of appendiceal adenocarcinoma with clinical benefit from folfox and bevacizumab |
| topic | Appendiceal adenocarcinoma FOLFOX Bevacizumab Clinical benefit Disease stability |
| url | http://www.karger.com/Article/FullText/229245 |
| work_keys_str_mv | AT erindpowell acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT dblairmacdonald acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT akrammelkeilani acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT timothyrasmis acaseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT erindpowell caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT dblairmacdonald caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT akrammelkeilani caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab AT timothyrasmis caseofappendicealadenocarcinomawithclinicalbenefitfromfolfoxandbevacizumab |